2 results match your criteria: "University of Washington School of Medicin[Affiliation]"
Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative.
Res Sq
June 2024
Weill Cornell Medicine, New York, NY.
Paxlovid has been approved for use in patients who are at high risk for severe acute COVID-19 illness. Evidence regarding whether Paxlovid protects against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or Long COVID, is mixed in high-risk patients and lacking in low-risk patients. With a target trial emulation framework, we evaluated the association of Paxlovid treatment within 5 days of SARS-CoV-2 infection with incident Long COVID and hospitalization or death from any cause in the post-acute period (30-180 days after infection) using electronic health records from the Patient-Centered Clinical Research Networks (PCORnet) RECOVER repository.
View Article and Find Full Text PDFSelf-detection remains a key method of breast cancer detection for U.S. women.
J Womens Health (Larchmt)
August 2011
University of Washington School of Medicin,eDepartment of Medicine,Division of Metabolism, Endocrinology and Nutrition, 1959 NE Pacific Street, Seattle, WA 98195-7138, USA.
Article Synopsis
- The study emphasizes the importance of detection methods for breast cancer in relation to long-term survival and treatment.
- It analyzes data from 361 women diagnosed with breast cancer between 1980 and 2003, highlighting different detection methods such as self-examination and mammograms.
- Results show that most survivors detected their cancer via non-mammographic methods, with a significant portion reporting self-examination or accidental discovery, suggesting that patient-reported abnormalities should be taken seriously.